SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
+1.73%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$124M
AUM Growth
+$124M
(-22%)
Cap. Flow
-$70.5M
Cap. Flow
% of AUM
-56.93%
Top 10 Holdings %
Top 10 Hldgs %
58.94%
Holding
58
New
20
Increased
13
Reduced
18
Closed
6
Top Buys
| 1 |
TELA Bio
TELA
|
$3.75M |
| 2 |
Inhibikase Therapeutics
IKT
|
$3.68M |
| 3 |
Inovio Pharmaceuticals
INO
|
$1.92M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$1.91M |
| 5 |
CalciMedica
CALC
|
$1.66M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$34.1M |
| 2 |
ADMA Biologics
ADMA
|
$10.8M |
| 3 |
Kezar Life Sciences
KZR
|
$9.28M |
| 4 |
Galapagos
GLPG
|
$7.66M |
| 5 |
Royalty Pharma
RPRX
|
$6M |
Sector Composition
| 1 | Healthcare | 99.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMRN
51
Amarin Corp
AMRN
$311M
| $55.4K | 0.04% |
+114,257
| New | +$55.4K |
|
52
Arcutis Biotherapeutics
ARQT
$1.86B
| – | – |
-88,457
| Closed | -$823K |
|
53
Rigel Pharmaceuticals
RIGL
$697M
| – | – |
-309,100
| Closed | -$5M |
|
|
54
Royalty Pharma
RPRX
$15.6B
| – | – |
-212,000
| Closed | -$6M |
|
55
Tenax Therapeutics
TENX
$27.3M
| – | – |
-50,000
| Closed | -$173K |
|
|
FNA
56
DELISTED
Paragon 28, Inc.
FNA
| – | – |
-114,724
| Closed | -$766K |
|
|
VIRX
57
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-500,000
| Closed | -$116K |
|